Fusing thymosin alpha-1 to an antibody Fc fragment extended its half-life 13-fold and produced stronger antitumor and immune-boosting effects against melanoma and breast cancer in mouse models.
13-fold half-life extensionTα1-Fc achieved a 25-hour serum half-life in mice vs. ~2 hours for native thymosin alpha-1, with stronger antitumor and immune-boosting activity
What the researchers found
The Tα1-Fc fusion protein achieved a serum half-life of 25 hours in mice — approximately 13 times longer than native Tα1. Production yielded approximately 160.4 mg/L at greater than 90.3% purity. In tumor models, Tα1-Fc showed stronger antitumor activity than Tα1 in both 4T1 (breast cancer) and B16F10 (melanoma) xenograft models. The mechanism involved upregulation of CD86 expression (dendritic cell activation), increased secretion of IFN-γ and IL-2 (immune cytokines), and greater tumor infiltration by CD4+ and CD8+ T cells. The fusion protein also showed stronger activity in repairing immune injury by increasing lymphocyte counts.
Why it matters
Thymosin alpha-1 is already an approved drug in several countries for hepatitis B, hepatitis C, and as an immune adjuvant in cancer therapy. Its main limitation is the need for frequent dosing due to rapid clearance. A long-acting version with enhanced immune-boosting activity could make Tα1-based cancer immunotherapy more practical and more effective, potentially complementing checkpoint inhibitors and other immunotherapies.
How the study worked
Researchers used genetic engineering to construct a Tα1-Fc (IgG4 Fc domain) fusion protein expressed in E. coli. Production was optimized using single-factor experiments with lactose induction. Pharmacokinetics were measured in mouse serum. Immune repair was assessed in immunocompromised mice (hydrocortisone-treated). Antitumor activity was tested in 4T1 breast cancer and B16F10 melanoma xenograft models, with immune cell infiltration and cytokine profiles measured.
What this study cannot tell us
This is a preclinical mouse study with xenograft tumor models, which may not accurately predict human responses. The Fc domain is from human IgG4, but the study was conducted in mice, raising questions about cross-species immune responses. No comparison with current standard immunotherapies (checkpoint inhibitors) was included. Long-term safety of the fusion protein was not assessed. The production was in E. coli, which doesn't glycosylate the Fc domain — this could affect function in humans.
How to read the evidence
This is a preclinical study demonstrating proof-of-concept for a novel Tα1 formulation in mouse tumor models. The production, pharmacokinetic, and efficacy data are well-characterized, but human translation has not been tested.
When this study was published
Published in 2018 in Scientific Reports, this study demonstrates a modification strategy that could be applied to thymosin alpha-1 programs currently in clinical development.
The bigger picture
Peptide therapeutics are often limited by short half-lives, and Fc fusion technology has been successfully used to extend the lifespan of other biologics (e.g., etanercept for inflammation). Applying this approach to thymosin alpha-1 addresses a key limitation and could revitalize interest in Tα1 as a cancer immunotherapy, particularly in combination with modern checkpoint inhibitors. The enhanced immune cell infiltration into tumors is especially relevant given that 'cold' tumors (with few immune cells) are resistant to immunotherapy.
Questions still open
- Could Tα1-Fc enhance the effectiveness of checkpoint inhibitors like pembrolizumab in cancer patients?
- Would the longer half-life translate proportionally to humans, and could weekly or biweekly dosing replace daily Tα1 injections?
- Does the IgG4 Fc domain contribute any antibody-mediated immune effects beyond simply extending the peptide's half-life?
Common questions
What is thymosin alpha-1 and why is it used in medicine?
How does attaching an Fc domain make the peptide work better?
Read the original research
Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life.
Scientific reports, 8(1), 12351
Citation
Wang, Fanwen; Yu, Tingting; Zheng, Heng; Lao, Xingzhen. (2018). Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life.. Scientific reports, 8(1), 12351. https://doi.org/10.1038/s41598-018-30956-y